NASDAQ:NBIX

Neurocrine Biosciences Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy NBIX

*Your capital is at risk

$165.11

+10.27 (+6.63%)

At Close: Jun 03, 2026

Neurocrine Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -60.71. In total, the insiders bought 1M and sold 337.42K NBIX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-60.71
● Buy	1M shares
● Sell	337.42K shares
77% Buy Activity Negligible or No Correlation
Sell Signal Medium Confidence May 19, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -60.71. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 13, 2026 Buy	Stock Option A-Award	Onyia Jude Chief Scientific Officer	Officer	55 119 Value: $6.84M
Feb 13, 2026 Buy	Common Stock A-Award	Onyia Jude Chief Scientific Officer	Officer	19 935 Value: $2.47M
Feb 13, 2026 Sell	Common Stock F-InKind	Onyia Jude Chief Scientific Officer	Officer	1 466 Value: $182.0K
Feb 13, 2026 Buy	Common Stock A-Award	Abernethy Matt Chief Financial Officer	C-Suite Officer	9 968 Value: $1.24M
Feb 13, 2026 Buy	Common Stock M-Exempt	Abernethy Matt Chief Financial Officer	C-Suite Officer	2 241 Value: $277.9K
Feb 13, 2026 Sell	Common Stock F-InKind	Abernethy Matt Chief Financial Officer	C-Suite Officer	1 385 Value: $171.9K
Feb 13, 2026 Buy	Restricted Stock Unit M-Exempt	Abernethy Matt Chief Financial Officer	C-Suite Officer	2 241 Value: $277.9K
Feb 13, 2026 Buy	Restricted Stock Unit M-Exempt	Abernethy Matt Chief Financial Officer	C-Suite Officer	2 566 Value: $318.2K
Feb 13, 2026 Sell	Common Stock F-InKind	Boyer David W. Chief Corp. Affairs Officer	Officer	832 Value: $103.3K
Feb 13, 2026 Buy	Restricted Stock Unit A-Award	Boyer David W. Chief Corp. Affairs Officer	Officer	5 479 Value: $679.4K
Feb 13, 2026 Buy	Restricted Stock Unit M-Exempt	Boyer David W. Chief Corp. Affairs Officer	Officer	1 541 Value: $191.1K
Feb 13, 2026 Buy	Common Stock A-Award	Gano Kyle Chief Executive Officer	CEO / President	9 968 Value: $1.24M
Feb 13, 2026 Buy	Common Stock M-Exempt	Gano Kyle Chief Executive Officer	CEO / President	2 241 Value: $277.9K
Feb 13, 2026 Sell	Common Stock F-InKind	Gano Kyle Chief Executive Officer	CEO / President	1 385 Value: $171.9K
Feb 13, 2026 Sell	Common Stock F-InKind	Gano Kyle Chief Executive Officer	CEO / President	1 210 Value: $150.2K
Feb 13, 2026 Buy	Stock Option A-Award	Gano Kyle Chief Executive Officer	CEO / President	114 830 Value: $14.3M
Feb 12, 2026 Sell	Common Stock F-InKind	Gano Kyle Chief Executive Officer	CEO / President	2 648 Value: $326.0K
Feb 12, 2026 Buy	Common Stock M-Exempt	Gano Kyle Chief Executive Officer	CEO / President	4 907 Value: $604.1K
Feb 12, 2026 Sell	Common Stock F-InKind	Abernethy Matt Chief Financial Officer	C-Suite Officer	1 151 Value: $141.7K
Feb 12, 2026 Buy	Common Stock M-Exempt	Onyia Jude Chief Scientific Officer	Officer	2 560 Value: $315.1K
Feb 12, 2026 Buy	Common Stock M-Exempt	Abernethy Matt Chief Financial Officer	C-Suite Officer	2 133 Value: $262.6K
Feb 12, 2026 Buy	Restricted Stock Unit M-Exempt	Abernethy Matt Chief Financial Officer	C-Suite Officer	2 133 Value: $262.6K
Feb 12, 2026 Buy	Common Stock M-Exempt	Boyer David W. Chief Corp. Affairs Officer	Officer	1 600 Value: $197.0K
Feb 12, 2026 Sell	Common Stock F-InKind	Boyer David W. Chief Corp. Affairs Officer	Officer	864 Value: $106.4K
Feb 12, 2026 Buy	Restricted Stock Unit M-Exempt	Boyer David W. Chief Corp. Affairs Officer	Officer	1 600 Value: $197.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT NEUROCRINE BIOSCIENCES

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ON...

Read Full Profile Here